MIMS Education

Improving treatment beyond efficacy in HER2-positive breast cancer

Improving treatment beyond efficacy in HER2-positive breast cancer

OncologySurgery
A badge with ribbon in color black 1.5 Points | An analog clock in color black 1 hour 30 mins | A black calendar with white triangle in center that has a black exclamation point in the middle 31 Dec 2023 

Overview

About this course

The availability of fixed-dose combination pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) has the potential to reduce the treatment burden on patients while maximizing healthcare resource utilization. Watch this CME-accredited video module to learn more.

Learning outcomes

Upon completing this module, participants will have a better understanding of the following aspects:
  • The efficacy and safety of PH FDC SC formulation
  • The clinical benefits of PH FDC SC over pertuzumab and trastuzumab intravenous (PH IV) formulation in the real-world setting
  • The practical guidance for selecting patients for PH FDC SC formulation

Topics covered

  • Current application of dual blockade for HER2-positive breast cancer
  • Clinical development of PH FDC SC
  • Clinical trials of PH FDC SC: Key efficacy, safety and patient preference data
  • Benefits of PH FDC SC on patients and the healthcare system
  • Practical guidance for selecting patients for PH FDC SC
  • PH FDC SC use in real-world clinical practice

CME Point(s) Available

  • This module is accredited for 1.5 CME points for fellows of Hong Kong College of Physicians, Hong Kong College of Radiologists and The College of Surgeons of Hong Kong.
  • Please note that this module will not earn CME credit for fellows of colleges not listed here.
  • A certificate can be downloaded upon successful completion of the quiz. Please use the information on the certificate to claim your CME point(s).

Organised by:

HKBCF Logo_600px.png

Supported by:

Roche_logo_500px.png


M-HK-00000720 Valid until 21/3/2024 or until change is required in accordance with the regulatory requirements, whichever comes first.